Skip to menu Skip to content Skip to footer

2020

Conference Publication

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

2020

Conference Publication

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study

Hawkes, Eliza Anne, Manos, Kate, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael Patrick, Keane, Colm, Scott, Andrew Mark, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison Anne, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2020). Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, May 29-31, 2020. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study

2019

Conference Publication

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

Nath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

2019

Conference Publication

y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Hawkes, Eliza A., Manos, Kate, Chong, Geoff, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze-Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2019). y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL USA, 7-10 December 2019. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2019-122635

y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

2019

Conference Publication

EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy

Gandhi, M.K., Hoang, T., Tobin, J.W., Law, S.C., Talaulikar, D., Jain, S., Vari, F., Murigneux, V., Fink, L., Gunawardana, J., Gould, C., Oey, H., Delecluse, S., Trappe, R.U., Merida de Long, L., Sabdia, M.B., Bhagat, G., Hapgood, G., Blyth, E., Clancy, L., Casey, J., Wight, J., Hawkes, E. and Keane, C. (2019). EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy. 15th International Conference on Malignant Lymphoma, Lugano, Switzerland, 18–22 June 2019. Oxford, United Kingdom: John Wiley & Sons. doi: 10.1002/hon.91_2629

EBV+ CNS lymphomas have a distinctive tumor microenvironment and genetic profile, which is amenable to combination 3rd party EBV-specific CTL and Ibrutinib therapy

2019

Conference Publication

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

Gould, Clare, Keane, Colm, Murigneux, Valentine, Oey, Harald, Ellis, Jonathan, Birch, Simone, Gunawardana, Jay, Talaulikar, Dipti, Hertzberg, Mark S., Jones, Kimberley and Gandhi, Maher K. (2019). B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL. ASH Annual Meeting, Orlando, FL, United States, 7-10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-126537

B2M Gene Expression Reflects an Immunologically Active Tumor Microenvironment in DLBCL

2018

Conference Publication

A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial

Abro, Emad Uddin, Law, Soi C., Keane, Colm, Birch, Simone, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Johnson, Peter, Trotman, Judith, Berkahn, Leanne, Fulham, Michael, Anderson, Richard A., Saunderson, Anne L., Gunawardana, Jay, Cross, Donna, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Law, W. P., Gill, Devinder and Gandhi, Maher K. (2018). A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial. 60th ASH Annual Meeting, San Diego, CA United States, 1-4 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-112008

A critical role for intratumoral and circulating LAG3 in classical Hodgkin Lymphoma: analysis from the Rathl prospective phase III international clinical trial

2018

Conference Publication

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

Tobin, J., Keane, C., Mollee, P., Birch, S., Gould, C., Gunawardana, J., Hoang, T., Savarimuthu, S., Ma, T., Li, L., Murigneux, V. , Fink, L., Matigian, N. and Gandhi, M. K. (2018). The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma. RACP Congress 2018, Disruption for Healthy Futures, Sydney, NSW Australia, 14–16 May 2018. Hoboken, NJ United States: Wiley. doi: 10.1111/imj.2_13826

The Tumour Microenvironment as an Independent Prognostic Biomarker in Follicular Lymphoma

2018

Conference Publication

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

Gunawardana, Jay, Bednarska, Karolina, Law, Soi C., Lee, Justina, Sabdia, Muhammed Bilal, Tobin, Joshua W. D., Birch, Simone, Keane, Colm and Gandhi, Maher K. (2018). The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego CA, United States, 1-4 December 2018. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2018-99-115836

The Tumor Microenvironment of Nodular Lymphocyte Predominant Hodgkin Lymphoma Is a Unique Immunobiological Entity Distinct from Classical Hodgkin Lymphoma

2018

Conference Publication

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

Keane, Colm, Law, Soi C., Gould, Clare, Francis, Santiyagu, Abro, Emad Uddin, Tobin, Joshua W. D., Birch, Simone, Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Talaulikar, Dipti, Gill, Anthony, Jain, Sanjiv, Cross, Donna, Hernadez, Annette, Halliday, Sarah-Jane, Bird, Robert, Hertzberg, Mark and Gandhi, Maher K. (2018). Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis. 60th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, United States, 1-4 December 2018. Washington, DC, Untied States: American Society of Hematology. doi: 10.1182/blood-2018-99-112830

Elevated LAG-3 111,xpression in the Tumor Microenvironement of Patients with DLBCL Is Associated with a Non-GCB Phenotype and Poor Prognosis

2017

Conference Publication

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

Tobin, Joshua W. D., Keane, Colm, Mollee, Peter, Birch, Simone, Gould, Clare, Gunawardana, Jay, Hoang, Thanh, Ma, Ti, Abro, Emad Uddin, Shanavas, Mohamed, Yoo, Hyung, Li, Li, Scuffham, Paul, Murigneux, Valentine, Fink, Lynn, Matigian, Nicholas, Vari, Frank, Francis, Santiyagu and Gandhi, Maher K. (2017). The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood.V130.Suppl_1.728.728

The tumor microenvironment is independently prognostic of conventional and clinicogenetic risk models in follicular lymphoma

2017

Conference Publication

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

Shanavas, Mohamed, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Tobin, Joshua W. D., Mathews, Marina, Francis, Santiyagu, Vari, Frank, Gandhi, Maher K. and Keane, Colm (2017). The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial

2017

Conference Publication

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

Gandhi, Maher K., Keane, Colm, Tobin, Joshua W. D., Talaulikar, Dipti, Jain, Sanjiv, Vari, Frank, Kruze, Lutz, Murigneux, Valentine, Fink, Lynn, Gunawardana, Jithendra, Gould, Clare, Oey, Harold, Fink, Susanne, Trappe, Ralf Ulrich, Mathews, Marina, Francis, Santiyagu and Hoang, Thanh (2017). The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA, United States, 9-12 December 2017. Washington, DC, United States: American Society of Hematology.

The impact of EBV upon the tumor microenvironment and mutational profile of primary CNS lymphoma in PTLD

2017

Conference Publication

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

Tobin, Joshua W. D., Royle, Jane, Mason, Robert, Michael, Millward, Lydia, Warburton, Sandhu, Shahneen, Haydon, Andrew, Long, Georgina, Carlino, Matteo, Smith, Jessica L., Dearden, Helen, Mollee, Peter, Gill, Devinder, Mapp, Sally, Atkinson, Victoria and Keane, Colm (2017). The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia. 59th Annual Meeting of the American-Society-of-Hematology (ASH), Atlanta, GA United States, 9-12 December 2017. Washington, DC United States: American Society of Hematology.

The Effect of Immune Checkpoint Inhibitors in Patients with Concomitant Advanced Melanoma and Chronic Lymphocytic Leukaemia

2016

Conference Publication

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

Gandhi, Maher K., Arpon, David, Keane, Colm, Han, Erica, Tobin, Josh, Bird, Robert, Hertzberg, Mark S., Self, Marlene, Cross, Donna, Hernandez, Annette and Vari, Frank (2016). A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma. 58th Annual Meeting and Exposition of the American-Society-of-Hematology, San Diego CA, United States, 3-6 December 2016. Washington, DC United States: American Society of Hematology.

A Novel Anti-Lymphoma Immune Evasion Mediated By the Interaction Between PD-1 Enriched NK-Cells and CD163+PD-L1+PD-L2+Tumor Associated Macrophages, That Is More Prominent in Hodgkin Lymphoma Than Diffuse Large B-Cell Lymphoma

2015

Conference Publication

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

Scherer, Florian, Kurtz, David Matthew, Green, Michael Richard, Newman, Aaron M., Klass, Daniel M., Zhou, Li, Krishnan, Rashi, Liu, Chih Long, Glover, Cynthia, Ohgami, Robert S., Hicks, Rodney J., Keane, Colm, Kong, Katherine A., Faham, Malek, Hertzberg, Mark S., Gandhi, Maher K., Advani, Ranjana H., Levy, Ronald, Diehn, Maximilian and Alizadeh, Ash A. (2015). Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL). Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, United States, May 29-June 2, 2015. Alexandria, United States: American Society of Clinical Oncology.

Pre-treatment circulating tumor DNA as a biomarker for disease burden in diffuse large B cell lymphoma (DLBCL)

2015

Conference Publication

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

Keane, Colm, Jones, Kimberly, Gould, Clare, Hamm, David, Wood, Peter, Birch, Simone, Crooks, Pauline, Green, Michael R., Taulaulikar, Dipti, Jain, Sanjiv, Tobin, Josh and Gandhi, Maher K. (2015). The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL). 55th Annual Meeting and Exposition of the American-Society-of-Hematology, New Orleans, LA, United States, 7-10 December 2013. WASHINGTON: AMER SOC HEMATOLOGY.

The T Cell Receptor (TCR) Repertoire Is a Key Determinant of the Tumour Microenvironment (TME) in Diffuse Large B Cell Lymphoma (DLBCL)

2015

Conference Publication

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

Lecao K.-A., Keane C., Han E., Talaulikar D. and Gandhi M. (2015). Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios. Scientific Stream at Big Data in Health Analytics 2015, BigData 2015, Sydney; Australia, October 20, 2015-October 21, 2015. Aachen, Germany: Rheinisch-Westfaelische Technische Hochschule Aachen.

Improving conventional prognosticators in diffuse large B cell lymphoma using marker ratios

2014

Conference Publication

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

Kurtz, David Matthew, Green, Michael R., Bratman, Scott Victor, Liu, Chih-Long, Glover, Cynthia, Keane, Colm, Kong, Katie, Faham, Malek, Miklos, David Bernard, Advani, Ranjana H., Levy, Ronald, Hertzberg, Mark S., Gandhi, Maher K., Diehn, Maximilian and Alizadeh, Ash A. (2014). Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL. 50th Annual Meeting of the American Society of Clinical Oncology, Chicago IL United States, May 30-June 3, 2014. Alexandria VA, United States: American Society of Clinical Oncology.

Noninvasive monitoring of cellular versus acellular tumor DNA from immunoglobulin genes for DLBCL

2012

Conference Publication

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma

Gandhi, Maher K., Vari, Frank, Crooks, Pauline, Keane, Colm, Nourse, Jamie P., Seymour, Louise A., Ritchie, David, Gottlieb, David, Gill, Devinder and Jones, Kimberley (2012). Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma. 54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Atlanta GA, United States, 8-11 December 2012. Washington, DC United States: American Society of Hematology.

Serum CD163 and TARC in Combination As Disease Response Biomarkers in Classical Hodgkin Lymphoma